LOS ANGELES, Oct. 6 Today, Grifols SA (Grifols), a globalhealthcare company based in Barcelona, Spain, broke ground on a new 92,000square foot, intravenous immune globulin (IVIG) production facility at itsmanufacturing complex in Los Angeles, California. This new facility is theinitial realization of the $600 million long-range investment plan announcedin October 2007 to increase production for Grifols lifesaving coagulationtherapies, immune globulins and albumin. Based on construction schedules andrigorous regulatory licensing requirements, it is expected that the facilitywill become operational for production of the Company's new generation IVIGproduct in early 2013.
The new facility represents an expansion of Grifols' existingmanufacturing capabilities in Los Angeles. "We are committed to continuing togrow our state of the art facilities in Los Angeles and giving back to thecommunity through the creation of new employment opportunities and economicgrowth," said Gregory Rich, President of Grifols, Inc. the US subsidiary ofGrifols, SA. The new facility will provide approximately 300 new jobs to theLos Angeles community and represents an investment of greater than $50 million.
"We commend Grifols' increased commitment to the production of immuneglobulin therapy. Assuring continued access to this lifesaving medicine meanscountless people who live with primary immunodeficienies, such as my son, canlead healthy and productive lives," said Marcia Boyle, President and Founderof the Immune Deficiency Foundation, the national patient organization forpersons with primary immune diseases. Demand for IVIG has seen steady growthover the past ten years in the US, Europe and other international markets.
Grifols' new production facility will almost double the company's IVIGproduction capacity and will utilize the same proprietary technologies andprocess flow designs employed at the company's existing IVIG productionfacility in Barcelona, Spain that have been pioneered by Grifols EngineeringS.A., a wholly owned subsidiary of Grifols S.A. In effect, the new facilitywill be a twin of the Company's IVIG facility in Barcelona, Spain that waslicensed by the US Food and Drug Administration (FDA) last year.
Building this additional production capacity represents one more step inGrifols' multi-year global growth plan to meet increasing patient need forlifesaving plasma therapies. Other elements of the long-range investment planinclude expanding plasma collection capacity and additional production andtesting facilities. Earlier this year the Company obtained FDA approval ofits state of the art bulk processing and aseptic filling facility at its LosAngeles manufacturing complex.
Grifols SA (Grifols) is a global healthcare company founded in 1940 inBarcelona, Spain. Today Grifols products and services are provided in morethan 90 countries around the world. Grifols specializes in the production ofplasma therapies to treat a variety of life-threatening diseases andconditions. Grifols operates 80 plasma donor centers throughout the US andhas manufacturing facilities located in Barcelona, Spain and Los Angeles,California. For more information about Grifols please visit www.grifols.com.
SOURCE Grifols SA